BeiGene, Ltd. (NASDAQ:BGNE) Shares Acquired by NewEdge Wealth LLC

NewEdge Wealth LLC lifted its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 7.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,612 shares of the company’s stock after purchasing an additional 112 shares during the quarter. NewEdge Wealth LLC’s holdings in BeiGene were worth $291,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BGNE. Baillie Gifford & Co. increased its holdings in BeiGene by 17.9% during the 3rd quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company’s stock valued at $696,384,000 after acquiring an additional 588,294 shares in the last quarter. BlackRock Inc. increased its holdings in BeiGene by 3.8% during the 1st quarter. BlackRock Inc. now owns 2,699,444 shares of the company’s stock valued at $509,114,000 after acquiring an additional 98,316 shares in the last quarter. FMR LLC increased its holdings in BeiGene by 3.0% during the 3rd quarter. FMR LLC now owns 2,352,730 shares of the company’s stock valued at $423,186,000 after acquiring an additional 69,297 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in BeiGene by 68.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 775,857 shares of the company’s stock valued at $167,222,000 after acquiring an additional 314,764 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in BeiGene by 10.9% during the 2nd quarter. Legal & General Group Plc now owns 284,661 shares of the company’s stock valued at $46,072,000 after acquiring an additional 27,945 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on BGNE shares. JPMorgan Chase & Co. raised their target price on shares of BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. Bank of America lowered their price target on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a report on Monday, April 8th. Guggenheim lowered their price target on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Finally, Sanford C. Bernstein lowered their price target on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a report on Wednesday, March 27th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $251.70.

BeiGene Price Performance

BGNE opened at $131.86 on Thursday. The company’s 50 day simple moving average is $155.97 and its 200 day simple moving average is $169.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32. BeiGene, Ltd. has a 1 year low of $131.28 and a 1 year high of $270.57. The stock has a market capitalization of $12.61 billion, a PE ratio of -15.51 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business had revenue of $634.40 million for the quarter, compared to analysts’ expectations of $632.52 million. During the same period last year, the company earned ($4.29) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. As a group, sell-side analysts expect that BeiGene, Ltd. will post -8.87 EPS for the current year.

Insider Buying and Selling

In other BeiGene news, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The sale was disclosed in a filing with the SEC, which is available at this link. In other BeiGene news, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,781 shares of company stock valued at $10,222,381. Insiders own 7.40% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.